Core Insights - Agios Pharmaceuticals announced that its sickle cell drug achieved one of its two primary objectives in a late-stage study involving patients aged 16 and older, but did not demonstrate a statistically significant reduction in the other primary endpoint [1] Group 1: Study Results - The drug met one of the two main goals in the late-stage study [1] - The study involved patients aged 16 and older [1] - The drug failed to show a statistically significant reduction in the second primary endpoint [1]

Jeremiah Buckley getting some news on Fizer this morning. For that, we're going to turn to Angelica Peoples. Hey, Angelica. >> Hey, Carl.Well, Fizer saying that one of its drugs for cickle cell disease has failed a phase three trial. Now, this is um you their hopes weren't particularly high for the cickle cell portfolio. But this is still important for Fizer because if you remember a few years ago, they spent about five billion dollars to acquire a company called Global Blood Therapeutics.And the deal has a ...